Thursday, 25 February 2021

Lupin receives FDA approval for Sevelamer Carbonate tabs

25 January 2021 | News

Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis

Source credit: Shutterstock

Source credit: Shutterstock

Lupin Limited, a global pharmaceutical company, announced that it has received approval for its Sevelamer Carbonate tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela® tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate tablets (RLD: Renvela®) had estimated annual sales of $348 million in thUS (IQVIA MAT September 2020).

 

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls